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Sequence speciﬁc DNA cleavage
a b s t r a c t
CRISPR/Cas systems mediate bacterial adaptive immune responses that evolved to protect bacteria from
bacteriophage and other horizontally transmitted genetic elements. Several CRISPR/Cas systems exist
but the simplest variant, referred to as Type II, has a single effector DNA endonuclease, called Cas9,
which is guided to its viral DNA target by two small RNAs, the crRNA and the tracrRNA. Initial efforts to
adapt the CRISPR/Cas system for DNA editing in mammalian cells, which focused on the Cas9 protein
from Streptococcus pyogenes (Spy), demonstrated that Spy Cas9 can be directed to DNA targets in
mammalian cells by tracrRNA:crRNA fusion transcripts called single guide RNAs (sgRNA). Upon binding,
Cas9 induces DNA cleavage leading to mutagenesis as a result of error prone non-homologous end
joining (NHEJ). Recently, the Spy Cas9 system has been adapted for high throughput screening of genes
in human cells for their relevance to a particular phenotype and, more generally, for the targeted
inactivation of speciﬁc genes, in cell lines and in vivo in a number of model organisms. The latter aim
seems likely to be greatly enhanced by the recent development of Cas9 proteins from bacterial species
such as Neisseria meningitidis and Staphyloccus aureus that are small enough to be expressed using
adeno-associated (AAV)-based vectors that can be readily prepared at very high titers. The evolving
Cas9-based DNA editing systems therefore appear likely to not only impact virology by allowing
researchers to screen for human genes that affect the replication of pathogenic human viruses of all
types but also to derive clonal human cell lines that lack individual gene products that either facilitate or
restrict viral replication. Moreover, high titer AAV-based vectors offer the possibility of directly targeting
DNA viruses that infect discrete sites in the human body, such as herpes simplex virus and hepatitis B
virus, with the hope that the entire population of viral DNA genomes might be destroyed. In conclusion,
we believe that the continued rapid evolution of CRISPR/Cas technology will soon have a major, possibly
revolutionary, impact on the ﬁeld of virology.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
Sequence speciﬁc DNA endonucleases were ﬁrst identiﬁed in the
1960s as enzymes that restrict the ability of DNA bacteriophage to
grow in particular bacterial isolates or species. Now called restriction
endonucleases, these proteins recognize short sequences of DNA,
often palindromic in nature, and cleave either within the recognition
sequence or nearby to destroy the incoming bacteriophage DNA
(Pingoud et al., 2014). The host DNA is protected by a modiﬁcation
enzyme that introduces a covalent modiﬁcation of a base, for
example methylation of an A residue, within the restriction enzyme
recognition sequence that prevents restriction enzyme function.
Incoming phage genomes that derive from bacteria lacking the
relevant modiﬁcation enzyme are in contrast highly susceptible to
cleavage. While restriction endonucleases played a key role in the
development of recombinant DNA research (Pingoud et al., 2014),
even the longest restriction endonuclease recognition sequences are
far too short to allow the speciﬁc, single site mutagenesis of large
viral genomes or, particularly, the mammalian host cell genome.
The ﬁrst technology to be developed with the potential to be
useful in the selective modiﬁcation of large viral or cellular DNA
genomes was the zinc ﬁnger endonuclease (ZFN) (Gaj et al., 2013;
Klug, 2010). Zinc ﬁngers are 30 amino acid long domains that have
the potential to speciﬁcally recognize many, but not all, 3 base pair
(bp) DNA sequences. Zinc ﬁngers function in a modular manner and
can therefore be arrayed to form a larger protein that can selectively
bind DNA sequences up to 18 bp in length, thus opening up the
possibility of binding unique sequences in the human genome. While
ZFNs do not themselves cleave the bound DNA, they can be fused
to a non-speciﬁc DNA endonuclease to allow DNA cleavage to occur
(Gaj et al., 2013; Klug, 2010). The most common approach is to fuse
the ZFN to the FokI endonuclease, which is only active upon for-
mation of a FokI homodimer. By designing two ZFNs that target
adjacent DNA sequences on opposite strands of the target genome,
the binding of the two ZFNs can induce the dimerization of the fused
FokI enzymes to generate an active dimer that cleaves precisely
between the two binding sites. This dsDNA break is most commonly
repaired by the error-prone non-homologous DNA end joining
(NHEJ) pathway, which can result in small indels being introduced
at the cleaved target site. Conversely, if NHEJ is precise, the target site
will be reconstituted to allow a second round of cleavage, and this
futile cycle will continue until a mutation is introduced that prevents
ZFN recognition and further cleavage events.
While ZFNs have proven to be very useful for both mammalian
cell DNA editing and inhibition of DNA virus replication, each zinc
ﬁnger is not necessarily highly speciﬁc for the 3 bp target that it is
designed to bind and zinc ﬁngers speciﬁc for all possible 3 bp target
sequences have not yet been derived (Gaj et al., 2013). To address this
perceived deﬁciency, a second technology, transcription activator like
endonucleases (TALENs) was developed, based on a distinct modular
DNA binding motif. TALENs are made up of four 34 aa domains,
derived from a DNA binding protein found in the pathogenic plant
bacterium Xanthomonas, that each recognize a single DNA base pair
with high speciﬁcity (Christian et al., 2010; Gaj et al., 2013; Miller
et al., 2011). As in the case of ZFNs, these modular domains can be
arrayed to recognize essentially any DNA sequence. Again, the
strategy is to construct two distinct DNA binding domains by
sequential addition of single base pair-speciﬁc modules until a
protein speciﬁc for the two chosen target sequences is derived. These
target sequences are again chosen to be adjacent, on opposite DNA
strands, and the two expressed TALENs again consist of fusions of
these artiﬁcial DNA binding domains to the FokI endonuclease, to
permit the highly speciﬁc cleavage of the DNA at a site located
between the two TALEN recognition sequences (Christian et al., 2010;
Miller et al., 2011). Each TALEN is generally designed to recognize an
16 bp DNA sequence that is close to unique in the cell of interest
and the TALEN heterodimer therefore recognizes an 32 bp
sequence, which is certainly large enough to ensure that no off-
target cleavage events will occur. While perhaps more speciﬁc than
ZFNs, TALENs require a rather laborious exercise in genetic engineer-
ing and are quite large, thus limiting the ability to express TALENs
using viral vectors.
While ZFNs and TALENs remain useful reagents for targeted gene
editing, it seems likely that they will in future be largely superseded
by the newly developed CRISPR/Cas based systems, which are both
highly speciﬁc and allow facile retargeting to new genomic loci
(Barrangou and Marrafﬁni, 2014; Cong et al., 2013; Hsu et al., 2014;
Mali et al., 2013). Clustered regularly interspaced short palindromic
repeats (CRISPR) loci are found in a wide range of bacteria and have
now been shown to be transcribed to generate a family of targeting
RNAs speciﬁc for a range of different DNA bacteriophage that can
infect that bacterium (Barrangou and Marrafﬁni, 2014; Hsu et al.,
2014). In bacteria that express a type II CRISPR/Cas system, these
phage-derived sequences are transcribed along with sequences from
the adjacent constant region to give a CRISPR RNA (crRNA) which
forms a complex with the invariant trans-activating RNA (tracrRNA),
using sequence complementarity between the tracrRNA and the
invariant part of the crRNA (Fig. 1). This heterodimer is then bound
by the effector protein of the type II CRISPR/Cas systems, called Cas9.
Cas9 has the ability to directly recognize a short DNA sequence,
50-NGG-30 for the commonly used Streptococcus pyogenes (Spy) Cas9
protein, called the protospacer adjacent motif (PAM) (Barrangou and
Marrafﬁni, 2014; Cong et al., 2013; Hsu et al., 2014; Mali et al., 2013).
The Cas9 protein scans a target genome for the PAM sequence and
then binds and queries the DNA for full 50 sequence complementarity
to the variable part of the crRNA. If detected, the Cas9 protein directly
cleaves both strands of the target bacteriophage DNA 3 bp 50 to the
PAM, using two distinct protein domains: the Cas9 RuvC-like domain
cleaves the non-complementary strand, while the Cas9 HNH nucle-
ase domain cleaves the complementary strand (Gasiunas et al., 2012;
Jinek et al., 2012). This dsDNA break then induces the degradation of
the phage DNA genome and blocks infection (Fig. 1) (Garneau et al.,
2010; Gasiunas et al., 2012; Sapranauskas et al., 2011).
A key step forward in making the Spy Cas9 system more user-
friendly for genetic engineering in human cells was the demonstra-
tion that the crRNA and tracrRNA could be linked by an artiﬁcial loop
sequence to generate a fully functional small guide RNA (sgRNA)
100 nt in length (Fig. 1) (Cong et al., 2013; Mali et al., 2013). Further
work, including mutational analysis of DNA targets, has revealed that
sequence speciﬁcity for Spy Cas9 relies both on the PAM and on full
complementarity to the 30 13 nt of the 20 nt variable region of
the sgRNA, with more 50 sequences making only a minor contribu-
tion (Fig. 1). Spy Cas9 therefore has an 15 bp (13 bp in the guide
and 2 bp in the PAM) sequence speciﬁcity which, while high, is
generally not sufﬁcient to entirely avoid a small number of potential
off-target cleavage sites in the large genome present in human cells.
Nevertheless, this is a high level of speciﬁcity and a small number of
off-targets in non-transcribed regions of the human genome appear
unlikely to be highly problematic, especially if due diligence is
devoted to bioinformatic analysis of potential off-target cleavage
sites. Moreover, this concern can be dealt with by mutating the Cas9
protein to inactivate one of the two independent HNH and RuvC
nuclease sites, to generate a so-called “nickase” (Cong et al., 2013;
Ran et al., 2013). It is then possible to target two nickase Cas9s to two
closely proximal (o20 bp) sites on the two strands of the DNA
target. Once nicked on both strands, the DNA will fall apart to give a
staggered dsDNA break, analogous to what is obtained upon cleavage
at a single recognition sequence using wild-type Spy Cas9, except
that the DNA target speciﬁcity is now 30 bp, amply sufﬁcient to
ensure complete speciﬁcity even in a large genome, such that present
in human cells. As in the case of cleavage by ZFNs or TALENs, this
dsRNA break is repaired by NHEJ resulting in an indel, which blocks
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further cleavage, or resulting in perfect repair, which results in an
additional round of cleavage by Cas9 (Fig. 1).
While the Spy CRISPR/Cas system allows the speciﬁc cleavage
and mutagenesis of host cell genes, it can also be used for other
purposes. If a single-stranded DNA template complementary to the
cleavage site is provided in trans, homologous DNA repair is favored
over NHEJ, allowing the introduction of site-speciﬁc mutations or,
perhaps even more usefully, the repair of defective human genes
linked to particular disease states (Cong et al., 2013; Schwank et al.,
2013; Wu et al., 2013). Moreover, it is possible to mutate Cas9 so it is
no longer capable of DNA cleavage, yet retains full DNA binding
capacity (Qi et al., 2013). These cleavage incompetent Cas9 proteins
can then be fused to various effector domains, for example
transcriptional activation or repression domains, and targeted to
the promoter regions of cellular genes that you wish to turn on or
off (Barrangou and Marrafﬁni, 2014; Hsu et al., 2014; Qi et al., 2013).
While CRISPR/Cas systems will therefore no doubt have a dramatic
effect on numerous aspects of biology and medicine, our focus here
is on the speciﬁc DNA cleavage activity of Cas9/sgRNA combinations
and our thoughts on how they will affect the future of virology
research and also potentially the treatment of speciﬁc viral diseases.
Using CRISPR/Cas to inactivate or mutate DNA virus genomes
The idea of using sequence-speciﬁc DNA endonucleases to target
and destroy DNA viruses has been around for some time (Schiffer
et al., 2012), with earlier work describing the use of ZFNs, TALENs or
a third type of endonuclease, called a homing endonuclease, to
target hepatitis B virus (HBV), human papillomavirus (HPV) and
herpes simplex virus type 1 (HSV-1) with varying degrees of
success (Aubert et al., 2014; Bloom et al., 2013; Chen et al., 2014;
Cradick et al., 2010; Grosse et al., 2011; Mino et al., 2006; Weber
et al., 2014). This work has now been extended, in our laboratory
and elsewhere, to the use of Spy-derived Cas9/sgRNA combinations,
delivered by lentiviral vector transduction or transfection, to induce
the mutational inactivation of the DNA genomes of HBV, HPV and
HIV-1 (Ebina et al., 2013; Hu et al., 2014a; Hu et al., 2014b; Kennedy
et al., 2015; Kennedy et al., 2014; Lin et al., 2014; Zhen et al., 2014).
In the case of HPV, the efﬁcient mutational inactivation of the viral
E6 gene, which normally functions to block the activity of the
cellular tumor suppressor p53, results in activation of the p53
transcription factor and its downstream effectors, resulting in cell
cycle arrest and the apoptotic death of HPV-transformed cells
(Kennedy et al., 2014; Zhen et al., 2014). Similarly, in the case of
HBV, Cas9/sgRNA combinations targeted to the HBV reverse tran-
scriptase (RT), core or surface antigen genes result in a marked
inhibition of viral protein expression and loss of viral DNA mole-
cules, including the covalently closed circular DNA (cccDNA) mole-
cules that play a critical role in HBV persistence in patients even
in the face of treatment with nucleoside-based inhibitors of RT
function (Kennedy et al., 2015; Lin et al., 2014). Finally, expression of
HIV-1 speciﬁc Cas9/sgRNA combinations has been shown to both
block de novo infection, by cleaving the newly synthesized HIV-1
proviral DNA intermediate prior to integration into the host cell
genome, and to eradicate a pre-existing latent infection by targeting
sequences in the HIV-1 long terminal repeat (LTR), thus inducing
Fig. 1. The cleavage cycle of Cas9 RNA-guided DNA endonucleases. Starting at the upper left, Cas9 ﬁrst binds either a native tracrRNA/crRNA complex or a synthetic sgRNA. The
protospacer, or targeting portion of the crRNA/sgRNA, is depicted in red, the repeat region in black, and the tracrRNA portion in blue. Note the added joining loop shown in gray
in the case of the sgRNA. Next, the sgRNA-loaded Cas9 protein scans a dsDNA target for a PAM (lower left), and upon encountering one it initiates sgRNA-complementarity
interrogation of the 50 adjacent DNA sequence. If both full seed sequence complementarity and the PAM are present, dsDNA cleavage occurs. Subsequent to cleavage, non-
homologous end joining (NHEJ) will at times faithfully repair the lesion resulting in restoration of a fully functional DNA target that can re-enter the cleavage cycle. Alternatively,
the error-prone NHEJ process can lead to mutagenesis of the seed target region, resulting in the formation of a cleavage refractory DNA target bearing an indel.
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the excision of the provirus from the genome of the infected cell,
leaving behind a single LTR copy (Ebina et al., 2013; Hu et al.,
2014a).
While impressive, these studies were all performed in cultured
cells and can at best be considered proof-of-principle. In order to be
feasible as an in vivo treatment approach, two problems need to be
addressed. Firstly, although current data suggest that off-target
cleavage by Spy Cas9 is minimal, it is not zero and the safety of this
approach in vivo needs to be further demonstrated (Hsu et al., 2013;
Kuscu et al., 2014; Wu et al., 2014). Additional animal studies, above
and beyond the encouraging results already reported, therefore need
to be performed. Even more importantly, it is clear that methods for
the efﬁcient delivery of Cas9/sgRNA combinations to infected cells
in vivo need to be developed. Previous work has largely focused on
transfection, which is not feasible in vivo, or lentiviral vectors, which
are difﬁcult to produce at titers much above 108 infectious units (IU)
per ml. We therefore believe that CRISPR/Cas-based approaches to
the in vivo treatment of DNA virus infections will require the
development of vectors based on adeno-associated virus (AAV),
which can generally be concentrated to titers of Z1014 viral particles
per ml, a level of vector that has the potential to transduce all virus-
infected cells in a patient, especially if these are all found in a single
location, e.g., in the liver or speciﬁc neurons (Kotterman and Schaffer,
2014). Moreover, AAV-based vectors have a well-established record
of safety and do not integrate at signiﬁcant levels into the target cell
genome, thus avoiding the potential for insertional activation of
deleterious genes (Kotterman and Schaffer, 2014).
The problem with this approach is that AAV vectors have a
maximum packaging capacity of 4.7 kb, and this includes the AAV
inverted terminal repeats, which together occupy 290 bp, leaving
only 4.4 kb for heterologous DNA. As the Spy Cas9 gene, including
an essential added nuclear localization signal (NLS), is 4.2 kb in size,
this does not leave enough room for a pol II promoter and poly
(A) addition site for Cas9 expression as well as a pol III promoter and
sgRNA sequence. One possible approach to resolve this problem is to
express the Cas9 protein from one AAV vector and the sgRNA(s) from a
second AAV, but the required two hit kinetics for function are not
ideal, especially in vivo (Swiech et al., 2014). Rather, the way forward is
clearly to use one of the many smaller Cas9 proteins encoded by other
bacterial species. In particular, Neisseria meningitidis (Nme) encodes a
Cas9 protein with the PAM sequence 50-NNNNGATT-30 while Staphy-
lococcus aureus (Sau) encodes a Cas9 with the PAM sequence
50-NNGRRT-30, where R is purine (Esvelt et al., 2013; Hou et al.,
2013; Zhang and Ran, 2014). Both proteins are encoded by genes
3.2 kb in length, leaving ample room for two sgRNA cassettes, in
addition to all required regulatory elements, in an AAV vector context
(Fig. 2). In our hands, Sau Cas9 is at least as active, or possibly more
active, than Spy Cas9 on the same DNA target sequence and the
sequence speciﬁcity of Sau Cas9 appears to be comparable to Spy Cas9
(data not shown). Therefore, it now seems entirely feasible to move to
animal experiments that are designed to test the efﬁcacy and safety of
AAV-based Cas9/sgRNA vector systems.
While a number of DNA viruses are potential targets for
elimination using CRISPR/Cas, we will here focus on four viruses,
i.e., HBV, HSV, HPV and HIV-1.
Hepatitis B virus
HBV remains a major public health problem, with over 300
million people chronically infected worldwide (Komatsu, 2014).
These individuals have an 25% risk of dying from the conse-
quences of HBV infection, including hepatocellular carcinoma (HCC)
and cirrhosis, and 800,000 individuals are thought to die each
year due to HBV. An excellent vaccine for HBV is available, but this is
not helpful in individuals with pre-existing infection, is not fully
effective at preventing vertical transmission and is not given to all
children in resource limited contexts. As noted above, the HBV RT
can be effectively inhibited by nucleoside-based drugs but this does
not cure this infection due to the extraordinary stability of the viral
episomal cccDNA intermediate (Werle-Lapostolle et al., 2004).
Recent in vitro data demonstrate that HBV genomic DNA molecules,
including the cccDNA, can be effectively cleaved and mutationally
inactivated by Cas9/sgRNA combinations in cells undergoing either
acute or chronic infections (Kennedy et al., 2015) and preliminary
evidence, using hydrodynamic injection to deliver both the HBV
DNA and an HBV-speciﬁc Cas9/sgRNA combination to the mouse
liver, is also consistent with the hypothesis that HBV-speciﬁc
Cas9/sgRNA combinations can block HBV replication and eliminate
the cccDNA pool if they can be effectively delivered to hepatocytes
(Lin et al., 2014). AAV may be ideal for this task, as several AAV
serotypes are naturally hepatotropic and even more highly hepato-
tropic AAV vectors have recently been isolated by “shufﬂing” AAV
sequences in vivo (Lisowski et al., 2014). The next step is clearly to
examine whether AAV-delivered Cas9/sgRNA combinations can
effectively cure HBV in the humanized, immunodeﬁcient mouse
liver model system, the best available preclinical model for HBV
replication in vivo (Dandri and Lutgehetmann, 2014).
Herpes simplex virus
HSV-1 infects 70% of the U.S. population and about one third of
affected individuals suffer from recurrent, primarily oral, cold sores.
HSV-1 most commonly initially infects the oral mucosal epithelium,
leading to a local productive infection, and then undergoes retro-
grade transport to the trigeminal ganglia, where it establishes a
latent infection in a small number of sensory neurons that persists
after the initial, productive infection is cleared by the host immune
response (Roizman et al., 2007). During latency, the HSV-1 DNA
genome is maintained as a nuclear episome, with from 1 to 50
copies per latently infected neuron. At this point, the only region of
the genome that is actively transcribed encodes the latency asso-
ciated transcript LAT, which is processed to give rise to a single long
non-coding RNA of 2.1 kb, as well as 8 virally encoded miRNAs,
that together are thought to regulate exit from latency (Umbach
et al., 2008). Importantly, no viral proteins are made, thus preventing
immune recognition of latently infected cells. Occasionally, generally
after some form of stress, one or more latently infected neuron is
activated to produce infectious virions that migrate down the axons
of the reactivating neuron to the original site of infection, where they
re-establish a transient productive infection that can lead to the
Fig. 2. A potential AAV multiplex Cas9 delivery vector. The minimal Cas9 protein from S. aureus has a total coding size of 3.2 kb, including an epitope tag and an NLS, and
this shorter Cas9 enzyme therefore opens up substantial packaging space in AAV. Minimal Pol II and Pol III promoters and a synthetic Poly A sequence can be employed to
minimize the nucleotide footprints of these cis-elements. In total, we have now generated small AAV-based CRISPR/Cas9 expression vectors that encode both the Sau Cas9
protein and two independent sgRNAs yet occupy o4.5 kb of packaging space, well below the AAV size limit of 4.7 kb.
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formation of cold sores. While often no more than an irritation,
HSV-1 infections can also lead to serious morbidity and HSV-1
keratitis represents the most common form of infectious blindness
in the USA (Liesegang, 2001). A closely related virus, HSV-2, that is
found in 20% of the US population, has a similar replication cycle
but generally is sexually transmitted and often infects the genital
mucosa. In the case of HSV-2, latency is established in sensory
neurons of the sacral ganglia and reactivation can lead to genital
ulcers. Again, serious morbidity is rare but does occur in some
individuals and neonatal HSV-2 infections acquired during vaginal
delivery can be fatal (Roizman et al., 2007).
While there are several drugs that can treat productive HSV-1 or
HSV-2 infections, generally by targeting viral DNA synthesis, latent
HSV genomes are entirely refractory to current treatment regimens
and it remains impossible to cure these infections. What is clearly
needed is an approach that directly targets HSV-1 or HSV-2 episomal
DNA for cleavage and elimination from latently infected neurons.
AAV-delivered HSV-speciﬁc Cas9/sgRNA combinations appear ideal
for this purpose (Chamberlin et al., 1998). In particular, several AAV
serotypes, including AAV8, are able to infect almost all (495%) of the
sensory neurons in the dorsal root ganglion after application of
particles of a green ﬂuorescent protein (gfp) expressing AAV8 vector
to the rear footpad of the mouse (D. Bloom, personal communica-
tion). Latent HSV-1 infections of neurons in the mouse trigeminal
ganglia (TGs) can be readily established and it is therefore possible to
test whether transduction of these same TGs with AAV8-based
vectors encoding HSV-1-speciﬁc Cas9/sgRNA combinations will
result in a detectable reduction in viral DNA load and an inhibition
in the ability of latent HSV-1 to reactivate after explant and culture of
the infected TGs. Given the tight localization of HSV-1 and HSV-2 to
the trigeminal and sacral ganglia respectively, given the low level of
viral DNA genomes present in these cells, and given the ability to
efﬁciently transduce sensory neurons with AAV8-based vectors, this
seems like an ideal viral candidate for cure using CRISPR/Cas.
Human papilloma virus
Humans are infected by a wide variety of HPVs that, while
normally innocuous, can also give rise to warts on the skin or
genitalia (Howley and Lowry, 2007). Most HPV variants replicate
as episomes in the basal epithelial layer of the skin, where the
virus expresses exclusively non-structural proteins. When the
infected precursor epithelial cell migrates towards the surface of
the epidermis and undergoes differentiation into a keratinocyte,
the productive HPV replication cycle is activated leading to the
release of infectious HPV virions (Howley and Lowry, 2007).
As noted above, most HPVs are non-pathogenic yet there are also a
small number of so-called high-risk HPV serotypes, of which the most
prominent are HPV-16 and HPV-18, which together cause 70% of all
cervical cancers. In most HPV induced cancers, the HPV episome is
found clonally integrated into the cell genome in a manner that
destroys or deletes the viral E2 gene (Howley and Lowry, 2007). The
role of the E2 protein is to bind to the HPV origin of replication, where
it functions to ensure the distribution of HPV episomes to both
daughter cells after cell division, and E2 also acts to regulate HPV early
gene transcription. One key activity of E2 is to limit the expression of
the HPV oncogenes E6 and E7, and disruption of E2 during integration
into the host cell genome can lead to high, constitutive levels of E6
and E7 expression (Thierry and Howley, 1991). E6 functions to bind
and destabilize the p53 tumor suppressor (Scheffner et al., 1990)
while E7 similarly binds and destabilizes the Rb tumor suppressor
(Mighty and Laimins, 2014)and these two functions play a critical role
in the maintenance of HPV-transformed cells. Cancers associated with
HPV infection include cervical carcinomas, which are almost always
HPV-positive, as well as a substantial fraction of head and neck (H&N)
cancers as well as anal cancers, all of which arise due to sexual
transmission of HPV. While cervical cancers can be detected early
using diagnostic tests and are generally readily cured by surgical
intervention, this is not the case for H&N and anal cancers, which are
usually treated by chemotherapy and radiation. While this is often
successful, a substantial percentage of anal and H&N cancers recur
locally, necessitating salvage surgery that can lead to signiﬁcant
morbidity. Therefore, a novel treatment regimen for chemoresistant
HPVþ tumors would be highly desirable. Of note, almost all HPVþ
H&N and anal cancers are HPV-16 positive, thus restricting the
required sequence range for a possible HPV-speciﬁc AAV-based
Cas9/sgRNA expression vector.
As noted above, both the HPV E6 and E7 proteins play a crucial role
in HPV tumorigenesis by blocking the action of p53 and Rb, respec-
tively (Mighty and Laimins, 2014). Consistent with this idea, inactiva-
tion of the E6 gene in the HPV-18þ cervical carcinoma cell line HeLa
or the HPV-16þ cell line SiHa using Spy CRISPR/Cas has been found to
result in induction of p53 expression followed by the expression of
downstream targets of this cellular transcription factor, including the
CDK inhibitor p21 and several activators of apoptosis, leading to cell
cycle arrest and cell death (Kennedy et al., 2014; Zhen et al., 2014).
Similarly, disruption of the E7 gene using CRISPR/Cas results in the
increased expression of Rb, formation of Rb/E2F heterodimers and
then the induction of cellular genes that induce senescence and cell
death (Hu et al., 2014b; Kennedy et al., 2014). Therefore, the delivery
of CRISPR/Cas combinations speciﬁc for HPV E6 and/or E7 by direct
injection of high titer AAV vector preparations into the HPVþ tumors
has the potential to serve as a novel, highly speciﬁc and effective
therapy for chemoresistant HPV-16 induced anal and H&N tumors.
Human immunodeﬁciency virus
While highly active antiretroviral therapy (HAART) can reduce
HIV-1 replication to levels below the detection limit, HIV-1 persists
as a latent infection in a small number of resting CD4þ memory T
cells (Chun et al., 1997). In these long lived cells, intact integrated
HIV-1 proviruses persist in a transcriptionally silent state that is
refractory to both drugs and host immune responses. However, these
memory T cells can be reactivated by an appropriate recall antigen,
resulting in induction of a productive viral replication cycle (Chun
et al., 1997; Wong et al., 1997). If this occurs after drug treatment has
been stopped, HIV-1 will rapidly spread through the available CD4þ
T cells and rekindle the same level of virus replication that was seen
prior to antiviral drug treatment.
Efforts to purge the pool of latently infected cells have focused on
two strategies. On the one hand, several groups have attempted to
activate latent HIV-1 proviruses using drugs, including histone deace-
tylase inhibitors and PKC agonists (Xing and Siliciano, 2013). However,
so far this strategy has not proven able to activate HIV-1 in a high
percentage of latently infected cells. An alternative strategy would be
to directly target and destroy latent proviruses using HIV-1-speciﬁc
CRISPR/Cas combinations and indeed two papers have shown that this
is feasible and that latent proviruses can in fact be excised from the
host cell genome, and then destroyed, by cleavage in the HIV-1 long
terminal repeat regions (Ebina et al., 2013; Hu et al., 2014a). In
principle, the HIV-1 provirus is a perfect target for CRISPR/Cas as
there is only a single proviral copy in the infected cell and, in the
presence of antiviral drugs, no spread of the virus is possible. The
problem, however, is that latently HIV-1 infected T cells are scattered
throughout the body and infecting all of these seems currently to be
an insurmountable problem, especially as T cells are poor targets for
AAV infection. This contrasts with HBV, HSV and HPV, all of which are
tightly localized in known tissues in the body that can be readily
targeted by AAV. Therefore, in the absence of novel vector delivery
systems that can target latently HIV-1 infected cells throughout the
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body, HIV-1 is likely to remain a technically challenging target for
elimination by CRISPR/Cas in vivo.
Other DNA viruses
A number of other DNA viruses are associated with serious
human diseases including Epstein-Barr virus (EBV), Kaposi's
sarcoma-associated herpesvirus (KSHV) and Merkel cell polyoma-
virus (MCPyV). Of these, perhaps the most relevant is EBV, which
is the etiologic agent of several cancers, including an epithelial cell
tumor called nasopharyngeal carcinoma (NPC) that is highly
prevalent in southern China and Southeast Asia (Rickinson and
Kieff, 2007). In NPC cells, EBV is found in a form of viral latency
that nevertheless involves the expression of several viral non-
structural proteins and microRNAs (Tsao et al., 2012). EBVþ NPCs
share a number of characteristics with HPV-16þ H&N cancers and,
as in the latter case, the continued presence and transcription of
the viral, in this case EBV, genome is thought to be essential for
tumor survival. It has already been demonstrated that EBV
episomes are readily disrupted and destroyed by speciﬁc Spy
Cas9/sgRNA combinations (Wang and Quake, 2014) and it seems
likely that NPC cells would be excellent targets for transduction
in vivo using Sau Cas9/sgRNA-based AAV vectors speciﬁc for the
EBV genome.
Using CRISPR/Cas to deﬁne cellular factors that facilitate
or restrict virus replication
Viruses have very compact genomes and therefore rely on the
host cell for many activities required to support their replication
cycle. Conversely, viruses are pathogens and put selective pressure
on their host organisms, thus selecting for cellular restriction factors
that can limit the level of viral replication. One of the best studied
viruses in this context is HIV-1, which requires a wide range of
human co-factors for replication in CD4þ T cells, several of which
are lacking in other mammalian species, such as in mice. Conversely,
HIV-1 is targeted by a wide range of human restriction factors and
dedicates a substantial portion of its coding capacity to the neu-
tralization of these restriction factors. For example, the HIV-1 Vif
protein blocks the activity of the host APOBEC3 family of restriction
factors, which otherwise interfere with the production of the HIV-1
provirus, while the HIV-1 Vpu protein neutralizes the cellular restri-
ction factor tetherin, which otherwise blocks the release of progeny
virions (Malim and Bieniasz, 2012).
The identity of cellular factors that either facilitate or restrict
virus replication is of great interest, not least because these can
provide targets for antiviral drug development. One approach to
their identiﬁcation has been to use RNA interference (RNAi) to
knock down the expression of human genes in order to identify
factors required for virus replication. However, while this
approach has led to some interesting insights, it is also clear
that RNAi screens for viral co-factors in different laboratories
have often led to very different lists of cellular proteins with this
potential activity. The reasons for this are unclear but probably
relate to the use of different cell systems, different assays for
viral replication and different RNAi reagents. As a result, most of
the viral co-factors and restriction factors identiﬁed so far have
in fact been deﬁned using biochemical approaches, for example
by identiﬁcation of cellular factors that speciﬁcally bind to a
viral protein, or genetic approaches, for example by comple-
mentation of a human and/or animal cell line that lacks a
particular co-factor or restriction factor (Malim and Bieniasz,
2012).
CRISPR/Cas systems appear highly suitable for use in screens
for non-essential viral co-factors or restriction factors, and indeed,
several screens for cellular factors involved in cell transformation
have been published (Shalem et al., 2014; Wang et al., 2014; Zhou
et al., 2014). This could now easily be extended to analysis of the
replication potential of, for example, gfpþ viruses in a 96-well or
384-well plate format. More generally, it seems likely that there
will soon be comprehensive CRISPR/Cas generated libraries of
cellular clones available for speciﬁc human cell lines that each
lack a human gene that is dispensable for cell viability in a tissue
culture setting. These clones would represent deﬁned reagents,
unlike the transient RNAi knockdown cells used previously, that
should allow the reproducible and almost complete identiﬁcation
of cellular factors that either help or hinder virus replication in
that human cell line in vitro. Of course, factors required for human
cell viability would be missed but it seems likely that almost all
host innate immune factors involved in restricting virus replica-
tion would not be essential and, while certainly factors required
for host cell viability are, by deﬁnition, also essential for virus
replication, such housekeeping functions are a priori less interest-
ing, especially as they clearly would not provide potential targets
for anti-viral drug development. In conclusion, we believe that the
development of effective CRISPR/Cas-based gene editing tools has
the potential to lead to the global identiﬁcation of almost all
cellular factors that regulate virus replication in culture, leading to
a wealth of new insights into viral molecular biology and produ-
cing numerous potential targets for antiviral drug development. If
such screens can indeed identify cellular factors that are required
for virus replication but entirely dispensable for the health of the
adult target organism, then it might be possible to also treat viral
infections, including RNA virus infections, via the localized abla-
tion of a cellular gene encoding such an essential viral co-factor
using AAV vector delivered CAS9/sgRNA combinations, as
described above for direct targeting of DNA virus genomes. Indeed,
a similar approach has previously been reported using ZFNs to
inactivate the HIV-1 co-receptor CCR5, to prevent the infection of
CD4þ T cells, by transduction of hematopoietic stem cells fol-
lowed by analysis of the production of HIV-1-resistant CD4þ
human T cells in engrafted immunodeﬁcient mice (Holt et al.,
2010; Li et al., 2013). Whether this latter approach is feasible in
human patients is, of course, currently unknown, but this possi-
bility does open up a range of potential new approaches to
targeted intervention in severe viral infections.
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